158 related articles for article (PubMed ID: 9836553)
1. Evaluation and management of men whose radical prostatectomies failed: results of an international survey.
Ornstein DK; Colberg JW; Virgo KS; Chan D; Johnson ET; Oh J; Johnson FE
Urology; 1998 Dec; 52(6):1047-54. PubMed ID: 9836553
[TBL] [Abstract][Full Text] [Related]
2. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States.
Sylvester J; Grimm P; Blasco J; Meier R; Spiegel J; Heaney C; Cavanagh W
Urology; 2001 Aug; 58(2 Suppl 1):65-70. PubMed ID: 11502452
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and management of the man who has failed primary curative therapy for prostate cancer.
Ornstein DK; Oh J; Herschman JD; Andriole GL
Urol Clin North Am; 1998 Nov; 25(4):591-601. PubMed ID: 10026768
[TBL] [Abstract][Full Text] [Related]
4. Current followup strategies after radical prostatectomy: a survey of American Urological Association urologists.
Oh J; Colberg JW; Ornstein DK; Johnson ET; Chan D; Virgo KS; Johnson FE
J Urol; 1999 Feb; 161(2):520-3. PubMed ID: 9915439
[TBL] [Abstract][Full Text] [Related]
5. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy.
Silverman JM; Krebs TL
AJR Am J Roentgenol; 1997 Feb; 168(2):379-85. PubMed ID: 9016212
[TBL] [Abstract][Full Text] [Related]
6. What to do for prostate cancer patients with a rising PSA?--A survey of Australian practice.
Duchesne GM; Millar JL; Moraga V; Rosenthal M; Royce P; Snow R
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):986-91. PubMed ID: 12605977
[TBL] [Abstract][Full Text] [Related]
7. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
8. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
9. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy.
Pound CR; Christens-Barry OW; Gurganus RT; Partin AW; Walsh PC
J Urol; 1999 Oct; 162(4):1337-40. PubMed ID: 10492192
[TBL] [Abstract][Full Text] [Related]
10. Practice trends in the diagnosis and management of prostate cancer in the United States.
Gee WF; Holtgrewe HL; Albertsen PC; Litwin MS; Manyak MJ; O'Leary MP; Painter MR
J Urol; 1995 Jul; 154(1):207-8. PubMed ID: 7539862
[TBL] [Abstract][Full Text] [Related]
11. Treatment of PSA only recurrence of prostate cancer after prior local therapy.
Moul JW
Curr Pharm Des; 2006; 12(7):785-98. PubMed ID: 16515495
[TBL] [Abstract][Full Text] [Related]
12. Urologists' personal feelings on PSA screening and prostate cancer treatment.
Wenzler DL; Rosenberg BH
J Eval Clin Pract; 2014 Aug; 20(4):408-10. PubMed ID: 24798149
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists.
Fowler FJ; Bin L; Collins MM; Roberts RG; Oesterling JE; Wasson JH; Barry MJ
Am J Med; 1998 Jun; 104(6):526-32. PubMed ID: 9674714
[TBL] [Abstract][Full Text] [Related]
14. Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using
Nehra A; Parker WP; Haloi R; Park SS; Mynderse LA; Lowe VJ; Davis BJ; Quevedo JF; Johnson GB; Kwon ED; Karnes RJ
J Urol; 2018 Mar; 199(3):726-733. PubMed ID: 28916273
[TBL] [Abstract][Full Text] [Related]
15. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
[TBL] [Abstract][Full Text] [Related]
16. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
18. The age of the urologist affects the postoperative care of prostate carcinoma patients.
Tsai DY; Virgo KS; Colberg JW; Ornstein DK; Johnson ET; Chan D; Johnson FE
Cancer; 1999 Oct; 86(7):1314-21. PubMed ID: 10506719
[TBL] [Abstract][Full Text] [Related]
19. Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey.
Surcel CI; Sooriakumaran P; Briganti A; De Visschere PJ; Fütterer JJ; Ghadjar P; Isbarn H; Ost P; Ploussard G; van den Bergh RC; van Oort IM; Yossepowitch O; Sedelaar JP; Giannarini G; ;
BJU Int; 2015 Apr; 115(4):571-9. PubMed ID: 24802335
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
Partin AW; Pearson JD; Landis PK; Carter HB; Pound CR; Clemens JQ; Epstein JI; Walsh PC
Urology; 1994 May; 43(5):649-59. PubMed ID: 7513108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
